Artigos

Laith J. Abu-Raddada,1, Lorenzo Sabatellia, Jerusha T. Achterberga,b,c, Jonathan D. Sugimotoa,b, Ira M. Longini, Jr.a,d, Christopher Dyee, and M. Elizabeth Hallorana,d,2

aVaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; Departments of bEpidemiology, cAnthropology, and dBiostatistics, University of Washington, Seattle, WA 98195; and eOffice of HIV/AIDS, Tuberculosis, Malaria, and Neglected Tropical Diseases, World Health Organization, CH-1211 Geneva 27, Switzerland Edited by Simon A. Levin, Princeton Universtiy, Princeton, NJ, and approved June 4, 2009 (received for review February 18, 2009)

Attachments:

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and dia

[ ]

619 kB

Madhukar Pai*, Andrew Ramsay, Richard O’Brien

Attachments:

Evidence-Based Tuberculosis Diagnosis

[ ]

141 kB

P. Daley,* J. S. Michael,† P. Hmar,† A. Latha,* P. Chordia,* D. Mathai,* K. R. John,‡ M. Pai§ 
* Department of Medicine, † Department of Microbiology, and ‡ Department of Community Health, Christian Medical College, Vellore, India; § Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada

Attachments:

Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculos

[ ]

113 kB

Keertan Dhedaa,b,c, Richard van Zyl Smita, Motasim Badria and Madhukar Paid

aDivision of Pulmonology, Department of Medicine, University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa, bCentre for Infectious Diseases and International Health, University College London Medical School, London, UK, cInstitute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa and dDepartment of Epidemiology & Biostatistics, McGill University, Montreal, Canada Correspondence to Keertan Dheda, MBBCh, FCP(SA), FCCP, PhD (Lond), Associate Professor of Respiratory Medicine, Lung Infection and Immunity Unit, Division of Pulmonology & Clinical Immunology, Department of Medicine, University of Cape Town, J flr. Old Main Bldg., Groote Schuur Hospital Observatory, 7925 Cape Town, South Africa
Tel: +27 21 4066509; fax: +27 21 4486815;
e-mail: Este endereço de email está sendo protegido de spambots. Você precisa do JavaScript ativado para vê-lo. or Este endereço de email está sendo protegido de spambots. Você precisa do JavaScript ativado para vê-lo. 
Current Opinion in Pulmonary Medicine 2009,
15:188–200

Attachments:

508_PUB_ART_Dheda_Curr_Op_Pulm_Med_2009.pdf

[ ]

283 kB

Peter Daley1, Joy Sarojini Michael2, Kalaiselvan S1, Asha Latha1, Dilip Mathai1, K. R. John3, Madhukar Pai4*
1 Department of Medicine, Christian Medical College Vellore, Vellore, India, 2 Department of Microbiology, Christian Medical College Vellore, Vellore, India, 3 Department of Community Health, Christian Medical College Vellore, Vellore, India, 4 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

Attachments:

505_PUB_art_Daley_PLoSOne_2009.pdf

[ ]

167 kB

Madhukar Pai, MD, PhD; Alice Zwerling, MSc; and Dick Menzies, MD, MSc

Background: Interferon- γ –release assays (IGRAs) are alternatives to the tuberculin skin test (TST). A recent meta-analysis showed that IGRAs have high specificity, even among populations that have received bacille Calmette–Gue´ rin (BCG) vaccination. Sensitivity was suboptimal for TST and IGRAs.

Purpose: To incorporate newly reported evidence from 20 studies into an updated meta-analysis on the sensitivity and specificity of IGRAs.

Attachments:

509_PUB_ART_Pai_Annals_2008.pdf

[ ]

253 kB

Madhukar Pai, M.D., Ph.D.1 and Richard O’Brien, M.D.2

ABSTRACT
Tuberculosis (TB) continues to be the world’s most important infectious cause of morbidity and mortality among adults. Nearly 9 million people develop TB disease each year, and an estimated 1.6 million die from the disease. Despite this enormous global burden, case detection rates are low, posing serious hurdles for TB control. Conventional TB diagnosis continues to rely on antiquated tests such as sputum smear microscopy, culture, tuberculin skin test, and chest radiography. These tests have several limitations and perform poorly in populations affected by the HIV epidemic. Conventional tests for detection of drug resistance are time consuming, tedious, and inaccessible in most settings.

Attachments:

'Brien_SRCCM_2008.pdf

[ ]

640 kB

M. Pai,*† R. Joshi,‡§ S. Dogra,¶ A. A. Zwerling,*† D. Gajalakshmi,‡ K. Goswami,‡ M. V. R. Reddy,‡ S. Kalantri,‡ P. C. Hill,# D. Menzies,*† P. C. Hopewell**
*Department of Epidemiology and Biostatistics, McGill University, Montreal, †Respiratory Epidemiology & Clinical Research Unit, Montreal Chest Institute, Montreal, Quebec, Canada; ‡Mahatma Gandhi Institute of Medical Sciences, Sevagram, India; §Division of Epidemiology, School of Public Health,  University of California, Berkeley, California, USA; ¶ASC College of Medical Sciences & Hospital, Sidhra, Jammu, India; #Centre for International Health, University of Otago, Dunedin, New Zealand; **Division of Pulmonary & Critical Care Medicine, San Francisco General Hospital and University of California, San Francisco, California, USA

Attachments:

510_PUB_ART_Pai_IJTLD_2009.pdf

[ ]

321 kB